Search

Your search keyword '"Vadasz, Zahava"' showing total 265 results
Start Over Author "Vadasz, Zahava"
265 results on '"Vadasz, Zahava"'

4. CD4+CCR5+ T cells and CCL3+ mast cells are increased in the skin of patients with chronic spontaneous urticaria.

Author

Mubariki, Raeda, Samara, Reem, Gimenez-Arnua, Anna Maria, Maurer, Marcus, Bejar, Jacob, Toubi, Elias, and Vadasz, Zahava

Subjects
MAST cells, T cells, CHEMOKINE receptors, INTERLEUKIN-17, CHEMOKINES, URTICARIA
Abstract

Background: The proximity of activated T cells and mast cells in the lesional skin of patients with chronic spontaneous urticaria (CSU) is held to contribute to the development of wheals and angioedema. In a previous study, we demonstrated that increased IL-17 expression in T cells and mast cells in skin lesions of patients with CSU is associated with T/mast cell proximity, but the mechanisms that drive T cell/mast cell co-localization remain unknown. Objectives: To assess if chemokines expressed in lesional CSU skin contribute to T cell/mast cell proximity. Patients and Methods: Biopsies from lesional CSU skin were compared to biopsies from healthy skin for expression of CCR5 and its ligand CCL3 by CD4+ T cells and mast cells, respectively. Results: Numbers of CCR5-positive CD4+ T cells in lesional CSU skin were significantly increased as compared to healthy normal skin (p < 0.0001). The number of mast cells expressing CCL3 (ligand for CCR5) in CSU skin was also increased (p < 0.0002) and significant association with T-cell close proximity (p < 0.0001) is noticed. Conclusions: The close proximity of T cells and mast cells in the skin of severe CSU may be driven, at least in part by increased CCR5 and CCL3 expression. Therapies that target CCL3 interaction with CCR5 should be assessed for their effects in CSU. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Soluble CD72, is a T-cell activator probably via binding to CD6 in homeostasis and autoimmunity.

Author

Eiza, Nasren, Sabag, Adi, Kessler, Ofra, Toubi, Elias, and Vadasz, Zahava

Subjects
AUTOIMMUNITY, REGULATORY B cells, HOMEOSTASIS, SJOGREN'S syndrome, SYSTEMIC lupus erythematosus
Abstract

Background: CD72 is a highly required regulatory molecule in B cells. Its sufficient expression is crucial for maintaining self-tolerance. In contrast, soluble CD72 (sCD72) is reported to be increased in the serum of autoimmune diseases such as systemic lupus erythematosus and primary Sjogren's syndrome (pSS). Objective: We wanted to assess the biological effect of sCD72 on CD4+T cells. Methods: We performed mass spectrometry and co-immunoprecipitation experiments to look for a sCD72 receptor on activated CD4+T cells. Afterward, to explore the biological functions of sCD72, we used flow cytometry for the cytokine secretion profile, a phosphorylation assay for the signaling pathway, and a CFSE dye-based assay for cell proliferation. Results: We found and validated the sCD72 and CD6 interaction as a possible ligand-receptor interaction. We also demonstrated that sCD72 significantly increases the expression of pro-inflammatory cytokines, namely IL-17A and IFN-g, in activated CD4+T cells and increases the proliferation of CD4+T cells, possibly through its activation of the SLP-76-AKT-mTOR pathway. Conclusion: The sCD72-CD6 axis on activated CD4+T cells is probably a new signaling pathway in the induction of immune-mediated diseases. Therefore, targeting sCD72 may become a valuable therapeutic tool in some autoimmune disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author

Zuberbier, Torsten, primary, Abdul Latiff, Amir, additional, Aggelidis, Xenofon, additional, Augustin, Matthias, additional, Balan, Radu‐Gheorghe, additional, Bangert, Christine, additional, Beck, Lisa, additional, Bieber, Thomas, additional, Bernstein, Jonathan A., additional, Bertolin Colilla, Marta, additional, Berardi, Alejandro, additional, Bedbrook, Anna, additional, Bindslev‐Jensen, Carsten, additional, Bousquet, Jean, additional, de Bruin‐Weller, Marjolein, additional, Bruscky, Dayanne, additional, Buyuktiryaki, Betul, additional, Canonica, Giorgio Walter, additional, Castro, Carla, additional, Chanturidze, Natia, additional, Chong‐Neto, Herberto Jose, additional, Chu, Chia‐Yu, additional, Chularojanamontri, Leena, additional, Cork, Michael, additional, Criado, Roberta F. J., additional, Barredo, Laia Curto, additional, Custovic, Adnan, additional, Darsow, Ulf, additional, Emurlai, Arben, additional, de Pablo, Ana, additional, Del Giacco, Stefano, additional, Girolomoni, Giampiero, additional, Deleva Jovanova, Tanja, additional, Deleuran, Mette, additional, Douladiris, Nikolaos, additional, Duarte, Bruno, additional, Dubakiene, Ruta, additional, Eller, Esben, additional, Engel‐Yeger, Batya, additional, Ensina, Luis Felipe, additional, Filho, Nelson Rosario, additional, Flohr, Carsten, additional, Fomina, Daria, additional, Francuzik, Wojciech, additional, Galimberti, Maria Laura, additional, Giménez‐Arnau, Ana M., additional, Godse, Kiran, additional, Mortz, Charlotte Gotthard, additional, Gotua, Maia, additional, Hide, Michihiro, additional, Hoetzenecker, Wolfram, additional, Hunzelmann, Nicolas, additional, Irvine, Alan, additional, Jack, Carolyn, additional, Kanavarou, Ioanna, additional, Katoh, Norito, additional, Kinaciyan, Tamar, additional, Kocatürk, Emek, additional, Kulthanan, Kanokvalai, additional, Lapeere, Hilde, additional, Lau, Susanne, additional, Machado Forti Nastri, Mariana, additional, Makris, Michael, additional, Mansour, Eli, additional, Marsland, Alexander, additional, Morelo Rocha Felix, Mara, additional, Moschione Castro, Ana Paula, additional, Nettis, Eustachio, additional, Nicolas, J. F., additional, Nosbaum, Audrey, additional, Odemyr, Mikaela, additional, Papapostolou, Niki, additional, Parisi, Claudio A. S., additional, Paudel, Sushil, additional, Peter, Jonny, additional, Pokharel, Prakash, additional, Puig, Luis, additional, Quint, Tamara, additional, Ramon, German Dario, additional, Regateiro, Frederico, additional, Ricci, Giampaolo, additional, Rosario, Cristine, additional, Sackesen, Cansin, additional, Schmid‐Grendelmeier, Peter, additional, Serra‐Baldrich, Esther, additional, Siemens, Kristina, additional, Smith, Cathrine, additional, Staubach, Petra, additional, Stevanovic, Katarina, additional, Su‐Kücük, Özlem, additional, Sussman, Gordon, additional, Tavecchio, Simona, additional, Teovska Mitrevska, Natasa, additional, Thaci, Diamant, additional, Toubi, Elias, additional, Traidl‐Hoffmann, Claudia, additional, Treudler, Regina, additional, Vadasz, Zahava, additional, van Hofman, Ingrid, additional, Ventura, Maria Teresa, additional, Wang, Zhao, additional, Werfel, Thomas, additional, Wollenberg, Andreas, additional, Yang, Ariana, additional, Weng Yew, Yik, additional, Zhao, Zuotao, additional, Zwiener, Ricardo, additional, and Worm, Margitta, additional

Published
2023
Full Text
View/download PDF

12. The Involvement of LAG-3 positive Plasma Cells in the Development of Multiple Myeloma.

Author

Kreiniz, Natalia, Eiza, Nasren, Tadmor, Tamar, Levy Yurkovski, Ilana, Matarasso Greenfeld, Sarah, Sabag, Adi, Mubariki, Raeda, Suriu, Celia, Votinov, Ekaterina, Toubi, Elias, and Vadasz, Zahava

Subjects
MULTIPLE myeloma, PLASMA cells, PROTEIN expression, PRECANCEROUS conditions, FLOW cytometry
Abstract

The Lymphocyte-Activation Protein 3 (LAG-3) inhibitory receptor is expressed on regulatory plasma cells (PCs). Micro-environmental cells that express LAG-3 were found to be increased during the progression of smoldering multiple myeloma (SMM). To assess the possible role of LAG-3 expression on regulatory PCs in patients with plasma cell dyscrasia. Purified Cluster of Differentiation 138 (CD138+) PCs from patients with premalignant conditions, active multiple myeloma (MM), and controls were analyzed for the expression of LAG-3 by flow cytometry. Autologous CD8+T cells were incubated with sorted LAG-3pos or LAG-3neg PCs for 24 h. The expression of granzyme (Grz) in CD8+T cells was assessed by flow cytometry. LAG-3 expression on PCs in active MM (newly diagnosed and relapse refractory MM) was significantly increased compared to monoclonal gammopathy of undetermined significance (MGUS)/ SMM. Grz expression was significantly decreased in CD8+T cells incubated with CD138+LAG-3pos PCs, compared to CD138+LAG-3neg PCs in patients with plasma cell dyscrasia, n = 31, p = 0.0041. LAG-3 expression on malignant PCs can be involved in the development of MM from MGUS by decreasing the expression of Grz in CD8+T cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. List of Contributors

Author

Afek, Arnon, primary, Afeltra, Antonella, additional, Afflitto, Gabriele Gallo, additional, Alessandri, Cristiano, additional, Alivernini, Stefano, additional, Alunno, Alessia, additional, Amital, Howard, additional, Andreoli, Laura, additional, Antonelli, Alessandro, additional, Arisi, Mariachiara, additional, Artusi, Carolina, additional, Atzeni, Fabiola, additional, Ballanti, Eleonora, additional, Barbati, Cristiana, additional, Barilaro, Giuseppe, additional, Bartoloni, Elena, additional, Ben-Ami, Dana, additional, Bettencourt, Andreia, additional, Bizzaro, Nicola, additional, Blank, Miri, additional, Bogdanos, Dimitrios P., additional, Boleixa, Daniela, additional, Borba, Vânia Vieira, additional, Borgiani, Paola, additional, Bragazzi, Nicola Luigi, additional, Brzosko, Iwona, additional, Brzosko, Marek, additional, Calzavara-Pinton, Piergiacomo, additional, Campi, Irene, additional, Cantarini, Luca, additional, Carranza-Muleiro, Rosa A., additional, Carvalho, Cláudia, additional, Caso, Francesco, additional, Ceccarelli, Fulvia, additional, Cervera, Ricard, additional, Chapman, Joab, additional, Chen, Xian, additional, Chimenti, Maria Sole, additional, Ciccacci, Cinzia, additional, Cipriano, Enrica, additional, Cohen Tervaert, Jan Willem, additional, Colasanti, Tania, additional, Conigliaro, Paola, additional, Conti, Fabrizio, additional, Coplan, Louis, additional, Costa, Luisa, additional, Croci, Stefania, additional, Cruz-Domínguez, María del Pilar, additional, Cutolo, Maurizio, additional, Dahan, Shani, additional, Damoiseaux, Jan, additional, De Carolis, Caterina, additional, Del Puente, Antonio, additional, Domingues, Vinicius, additional, Dreyfus, David H., additional, Drori, Tali, additional, Ehrenfeld, Michael, additional, Espinosa, Gerard, additional, Farina, Antonella, additional, Farina, Giuseppina Alessandra, additional, Ferraccioli, Gianfranco, additional, Finucci, Annacarla, additional, Fioravanti, Antonella, additional, Fischer, Katarzyna, additional, Fonti, Giulia Lavinia, additional, Francesca, Barone, additional, Franceschini, Franco, additional, Freire de Carvalho, Jozélio, additional, Fujio, Keishi, additional, García-Collinot, Grettel, additional, Generali, Elena, additional, Gerardi, Maria Chiara, additional, Gerli, Roberto, additional, Gertel, Smadar, additional, Giat, Eitan, additional, Greco, Elisabetta, additional, Gremese, Elisa, additional, Grunebaum, Eyal, additional, Gualtierotti, Roberta, additional, Guarino, Maria Domenica, additional, Guzner-Gur, Hanan, additional, He, Shu-Gui, additional, Iannuccelli, Cristina, additional, Jara, Luis J., additional, Jeandel, Pierre-Yves, additional, Kivity, Dr Shaye, additional, Kotyla, Przemyslaw J., additional, Krosser, Alec, additional, Latini, Andrea, additional, Leon-Ponte, Matilde, additional, Lerner, Aaron, additional, Levy, Roger Abramino, additional, Lichtbroun, Benjamin, additional, Lucchetti, Ramona, additional, Lu, Qianjin, additional, Margiotta, Domenico P.E., additional, Marinho, António, additional, Martínez-Bencomo, Michel A., additional, Matthias, Torsten, additional, Medina, Gabriela, additional, Meroni, Pier Luigi, additional, Lichtbroun, Michael, additional, Moreira Balbi, Gustavo Guimarães, additional, Muratore, Francesco, additional, Navarini, Luca, additional, Novelli, Giuseppe, additional, Pacucci, Viviana Antonella, additional, Peluso, Rosario, additional, Pendolino, Monica, additional, Pérez, Dolores, additional, Perricone, Carlo, additional, Perricone, Roberto, additional, Persani, Luca, additional, Petricca, Luca, additional, Pipitone, Nicolò, additional, Ramires de Jesús, Guilherme, additional, Resende, Gustavo, additional, Rizenbah, Chen, additional, Rodríguez-Pintó, Ignasi, additional, Rose, Noel R., additional, Rosenthal, Eric, additional, Rossi, Mariateresa, additional, Sakkas, Lazaros I., additional, Salvarani, Carlo, additional, Sarzi-Puttini, Piercarlo, additional, Scarpa, Raffaele, additional, Segal, Yahel, additional, Segel, Michael J., additional, Selmi, Carlo, additional, Seluk, Dr Lior, additional, Serena, Colafrancesco, additional, Sharabi, Amir, additional, Sharif, Kassem, additional, Shoenfeld, Netta, additional, Shoenfeld, Yehuda, additional, Signorelli, Flavio, additional, Silva, Ana Martins, additional, Silva, Berta Martins, additional, Slomovich, Sharon, additional, Somech, Raz, additional, Soriano, Alessandra, additional, Szekanecz, Zoltán, additional, Tanaka, Yoshiya, additional, Tenti, Sara, additional, Tincani, Angela, additional, Tolusso, Barbara, additional, Torres-Ruiz, Jiram, additional, Toubi, Elias, additional, Tozzoli, Renato, additional, Triggianese, Paola, additional, Trombetta, Amelia Chiara, additional, Tsokos, George C., additional, Tsuchida, Yumi, additional, Vadasz, Zahava, additional, Valesini, Guido, additional, van Beers, Joyce, additional, van Paassen, Pieter, additional, Vannucchi, Guia Maria, additional, Vasconcelos, Carlos, additional, Venturini, Marina, additional, Vera-Lastra, Olga, additional, Versini, Mathilde, additional, Vomero, Marta, additional, Watad, Abdulla, additional, Wu, Haijing, additional, and Zeng, Yong, additional

Published
2019
Full Text
View/download PDF

17. The Expression of IL-17, in Chronic Spontaneous Urticaria Is Linked to Semaphorin5A

Author

Matanis Lobna, Eiza Nasren, Sabag Adi, Bejar Jacob, Gimenez-Arnau Ana Maria, Maurer Marcus, and Vadasz Zahava

Subjects
chronic spontaneous urticaria, T cells, mast cells, semaphorin5A, IL-17, Microbiology, QR1-502
Abstract

Background: Patients with chronic spontaneous urticaria (CSU), an autoimmune disorder, show increased skin expression of IL-17A and can benefit from treatment with the anti-IL-17A biologic secukinumab. The mechanisms that drive IL-17A expression in CSU are currently unknown, but may involve Semaphorin5A (Sema5A). Objective: To explore the expression, role, and effects of Sema5A in CSU and its link to IL-17A. Material and Methods: We investigated patients with CSU and healthy controls for skin expression of expressing peripheral T cells. Results: Sema5A was highly expressed in the skin of CSU patients as compared to healthy control skin. Both CD4+ T cells and mast cells in CSU skin expressed Sema5A, and many of them expressed both Sema5A and IL-17A. Patients with CSU had significantly higher rates of IL-17A-expressing CD4+ T cells as compared to healthy controls. Incubation with Sema5A increased the rates of IL-17A-expressing CD4+ T cells in healthy controls to CSU levels. Conclusion: Sema5A may drive the expression and effects of IL-17A in CSU. Further studies in larger cohorts are needed to confirm the role of Sema5A in the pathogenesis of CSU and to explore its potential as a therapeutic target.

Published
2021
Full Text
View/download PDF

20. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, Salman, Andaç, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Câmara Agondi, Rosana, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta Fachini Jardim, De Souza Lima, Eduardo Magalhães, Demir, Semra, Dissemond, Joachim, Doğan Günaydın, Sibel, Dorofeeva, Irina, Ensina, Luis Felipe, Ertaş, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Giménez Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zając, Alicja, Katelaris, Constance H., Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M.Sendhil, Lang, Claudia, Larco-Sousa, José Ignacio, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Calderón llosa, Oscar, Makris, Michael, Marsland, Alexander, Medina, Iris V., Meshkova, Raisa, Bastos Palitot, Esther, Parisi, Claudio A.S., Pickert, Julia, Ramon, Germán D., Rodríguez-Gonzalez, Mónica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sánchez Caraballo, Jorge Mario, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, E, Song, Zhiqiang, Soria, Angèle, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B.A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yücel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, Maurer, Marcus, Universitat Autònoma de Barcelona, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A., Cherrez-Ojeda, I., Criado, P. R., Peter, J., Comert-Ozer, E., Abuzakouk, M., Agondi, R. C., Al-Ahmad, M., Altrichter, S., Arnaout, R., Arruda, L. K., Asero, R., Bauer, A., Ben-Shoshan, M., Bernstein, J. A., Bizjak, M., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Busse, P., Campos, R. A., Carne, E., Conlon, N., Criado, R. F., Lima, E. M. D., Demir, S., Dissemond, J., Gunaydin, S. D., Dorofeeva, I., Ensina, L. F., Ertas, R., Ferrucci, S. M., Figueras-Nart, I., Fomina, D., Franken, S. M., Fukunaga, A., Gimenez-Arnau, A. M., Godse, K., Goncalo, M., Gotua, M., Grattan, C., Guillet, C., Inomata, N., Jakob, T., Karakaya, G., Kasperska-Zajac, A., Katelaris, C. H., Kosnik, M., Krasowska, D., Kulthanan, K., Kumaran, M. S., Lang, C., Larco-Sousa, J. I., Lazaridou, E., Leslie, T. A., Lippert, U., Llosa, O. C., Makris, M., Marsland, A., Medina, I. V., Meshkova, R., Palitot, E. B., Parisi, C. A. S., Pickert, J., Ramon, G. D., Rodriguez-Gonzalez, M., Rosario, N., Rudenko, M., Rutkowski, K., Sanchez, J., Schliemann, S., Sekerel, B. E., Serpa, F. S., Serra-Baldrich, E., Song, Z. Q., Soria, A., Staevska, M., Staubach, P., Tagka, A., Takahagi, S., Thomsen, S. F., Treudler, R., Vadasz, Z., Valle, S. O. R., Van Doorn, M. B. A., Vestergaard, C., Wagner, N., Wang, D. H., Wang, L. C., Wedi, B., Xepapadaki, P., Yücel, E., Zalewska-Janowska, A., Zhao, Z. T., Zuberbier, T., Maurer, M., School of Medicine, AII - Infectious diseases, Kocaturk, Emek, Salman, Andac, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Agondi, Rosana Camara, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta F., de Souza Lima, Eduardo M., Demir, Semra, Dissemond, Joachim, Gunaydin, Sibel Dogan, Dorofeeva, Irina, Ensina, Luis Felipe, Ertas, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Gimenez-Arnau, Ana M., Godse, Kiran, Goncalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Lang, Claudia, Ignacio Larco-Sousa, Jose, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Llosa, Oscar Calderon, Makris, Michael, Marsland, Alexander, Medina, Iris, V, Meshkova, Raisa, Palitot, Esther Bastos, Parisi, Claudio A. S., Pickert, Julia, Ramon, German D., Rodriguez-Gonzalez, Monica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sanchez, Jorge, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, Esther, Song, Zhiqiang, Soria, Angele, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B. A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yucel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, and Maurer, Marcus

Subjects
Male, 0301 basic medicine, STRESS, Exacerbation, UCARE, pandemije, Medizin, Omalizumab, SERUM, chronic urticaria, 0302 clinical medicine, Pandemic, Health care, Immunology and Allergy, Chronic Urticaria, treatment, Chronic urticaria, COVID-19, Cyclosporine, SARS-CoV-2, Treatment, zdravljenje, ASSOCIATION, Middle Aged, cyclosporine, omalizumab, pandemic, kronična urtikarija, INFECTIONS, GA(2)LEN, Female, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Coronavirus disease 2019 (COVID-19), Immunology, udc:616-097, pandemics, ciklosporin, Young Adult, 03 medical and health sciences, Patient referral, medicine, Humans, In patient, Patient Reported Outcome Measures, Aged, Internet, business.industry, DEFINITION, Medicine, Allergy, Cross-Sectional Studies, 030104 developmental biology, 030228 respiratory system, Emergency medicine, business
Abstract

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation., Novartis; Sanofi; Menarini Universidad Espiritu Santo; Takeda; Allakos; AstraZeneca; CSL Behring; Genentech; Pharming; GSK; Shire/Takada; BioCryst; ResTORbio; Pearl Therapeutics, CVS Health; Law offices of Levin; Riback; Adelman; Flangel; Vedder Price; Fresenius; Taiho; Kyowa Kirin; Tanabe; Korin; Uriach Pharma; Instituto Carlos III FEDER; Menarini; Amgen; Thermo Fisher; Avene; ALK‐Abello; Bencard/Allergy Therapeutics; Celgene; Allergopharma; Faes Farma; AbbVie; Janssen; Leo Pharma; Lilly; Roche; Genesis; Menlo Therapeutics; UCB; Pfizer; Almirall; Galderma; Allergika; Beiersdorf; Biocryst; Biogen Idec; BMS; Boehringer‐Ingelheim; Eli‐Lilly; Galderma; Hexal; Klosterfrau; LEO‐Pharma; LETI‐Pharma; L´Oreal; Medice; Octapharma; Pflüger; Pharming; Regeneron; Shire; ALK‐Abello; Fraunhofer‐IZI Leipzig; Hautnetz Leipzig/Westsachsen; MSD; HAL‐Allergy; Bencard; Nestle; Nutricia; Bayer Health Care; FAES; Henkel; Allakos; Argenx; Genentech Menarini; Moxie; Aralez; Celldex

Published
2021

25. The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma

Author

Kreiniz, Natalia, primary, Eiza, Nasreen, additional, Tadmor, Tamar, additional, Sabag, Adi, additional, Matarasso Greenfeld, Sarah, additional, Levy, Ilana, additional, Surio, Celia, additional, Votinov, Ekaterina, additional, Mubariki, Raeda, additional, Polliack, Aaron, additional, Toubi, Elias, additional, and Vadasz, Zahava, additional

Published
2022
Full Text
View/download PDF

27. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients.

Author

UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, Hexner-Erlichman, Zufit, Veiga da Cunha, Maria, Zehavi, Yoav, Vadasz, Zahava, Sabag, Adi D, Tatour, Sameh, Spiegel, Ronen, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, Hexner-Erlichman, Zufit, Veiga da Cunha, Maria, Zehavi, Yoav, Vadasz, Zahava, Sabag, Adi D, Tatour, Sameh, and Spiegel, Ronen

Abstract

Glycogen storage disease type 1b (GSD1b) is an ultra-rare autosomal recessive disorder, caused by mutations in gene. Affected patients present with episodes of fasting hypoglycemia and lactic acidosis, hepatomegaly, growth retardation, hyperlipidemia and renal impairment. In addition, patients present neutropenia, neutrophil dysfunction and oral, and skin infections as well as a significant predisposition to develop inflammatory bowel disease (IBD). Low neutrophil counts and function is related to the toxic accumulation of 1,5-anhydroglucitol-6-phosphate (1,5-AG6P). Recently, several reports have shown that off-label treatment with empagliflozin (EMPA), an inhibitor of the renal glucose transporter SGLT2, decreased blood 1,5-anhydroglucitol (1,5-AG), and neutrophil 1,5-AG6P, thus resulting in a new therapeutic option for neutropenia and neutrophil dysfunction in patients. Off-label treatment with EMPA was established in two GSD1b patients after signed informed consent. The patients were followed clinically. We monitored neutrophil counts and function, 1,5-AG levels in plasma and its renal clearance before and during EMPA treatment. A 17 year-old girl who had long standing oral ulcers and developed IBD, requiring systemic steroid and regular granulocyte colony-stimulating factor (GCSF) therapy and an 8 year-old boy who had steady non healing oral lesions were treated with empagliflozin during 18-24 months. Treatment led to increase of neutrophil counts and function with substantial clinical improvement. This included remission of IBD in the first patient which allowed to discontinue both GCSF and steroid therapy and resolution of oral lesions in both patients. The concentration of 1,5-AG in blood was greatly decreased within two weeks of treatment and remained stable thereafter. Repurposing of empagliflozin to treat neutropenia in two GSD1b patients was safe and resulted in the urinary excretion of 1,5-AG, the normalization of neutrophil function, and a remarkable im

Published
2022

28. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez-Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, Maurer, Marcus, Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez-Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, and Maurer, Marcus

Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

Published
2022

33. Contributors

Author

Abdurakhmanov, Alexander, primary, Abu-Shakra, Mahmoud, additional, Afanasyeva, Marina, additional, Agmon-Levin, Nancy, additional, Albert, Paul J., additional, Almeida, Isabel, additional, Alves, Rute, additional, Amital, Howard, additional, Andrade, Paulo, additional, Antonelli, Alessandro, additional, Puccetti, Antonio, additional, Arango, María-Teresa, additional, Atzeni, Fabiola, additional, Baird, Alison E., additional, Balbir-Gurman, Alexandra, additional, Bashi, Tomer, additional, Batticciotto, Alberto, additional, Benucci, Maurizio, additional, Blank, Miri, additional, Bogdanos, Dimitrios P., additional, Bombardieri, S., additional, Borella, E., additional, Bosis, Samantha, additional, Bournia, Vasiliki Kalliopi, additional, Brandão, Mariana, additional, Braun-Moscovici, Yolanda, additional, Brender-Gotlieb, Neta, additional, Cainelli, Francesca, additional, Caldas, Cezar Augusto Muniz, additional, Campar, A., additional, Carvalheiras, Graziela, additional, Cervera, R., additional, Chapman, Joab, additional, Chastain, Emily M.L., additional, Claudio, Lunardi, additional, Cohen, Eytan, additional, Conti, Fabrizio, additional, Correia, J., additional, Carvalho, Jozélio Freire de, additional, Rossa, A. Della, additional, Detrick, Barbara, additional, Deutsch, Melanie, additional, Di Domenicantonio, Andrea, additional, Domeneghetti, M., additional, Domingues, Vital, additional, Doria, A., additional, Dow, Coad Thomas, additional, Dreyfus, David H., additional, Drouin, Elise E., additional, Dubaniewicz, Anna, additional, Durai, Malarvizhi, additional, Ebringer, Alan, additional, Ehrenfeld, Michael, additional, Elisa, Tinazzi, additional, Esposito, Susanna, additional, Fallahi, Poupak, additional, Faria, Raquel, additional, Farinha, Fátima, additional, Ferrannini, Ele, additional, Ferrari, Silvia Martina, additional, Ferreira, Alvaro, additional, Ferrão, C., additional, Garg, Ravindra Kumar, additional, Gatto, M., additional, Ghirardello, A., additional, Giovanna, Zanoni, additional, Giuseppe, Patuzzo, additional, Givaty, Gili, additional, Guilherme, Luiza, additional, Hammerstad, Sara Salehi, additional, Hodak, Emillia, additional, Hooks, John J., additional, Iaccarino, L., additional, Invernizzi, Pietro, additional, Israeli, Eitan, additional, Jamin, Christophe, additional, Janket, Sok-Ja, additional, Jarčuška, Peter, additional, Jones, Rodney P., additional, Kalil, Jorge, additional, Kanasi, Eleni, additional, Kivity, Shaye, additional, Konikoff, Tom, additional, Kozáková, D., additional, Krause, Ilan, additional, Lerner, Aaron, additional, Lidar, Merav, additional, Ling, Eduard, additional, Mahajna, Hussein, additional, Mahroum, Naim, additional, Maoz-Segal, Ramit, additional, Marinho, António, additional, Marshall, Trevor G., additional, Martinelli, Maria, additional, Marzia, Dolcino, additional, Mavragani, Clio P., additional, Mendonça, Teresa, additional, Miller, Stephen D., additional, Mimouni, Daniel, additional, Monteiro, Marta, additional, Moudgil, Kamal D., additional, Moulton, Vaishali R., additional, Moutsopoulos, Haralampos M., additional, Nagpal, Kamalpreet, additional, Neves, Esmeralda, additional, Nussenblatt, Robert, additional, Ollech, Ayelet, additional, Palma, L., additional, Pasoto, Sandra Gofinet, additional, Pella, Daniel, additional, Pereira, Cláudia, additional, Perricone, Carlo, additional, Petríková, Jana, additional, Proal, Amy D., additional, Rashid, Taha, additional, Reif, Shimon, additional, Renaudineau, Yves, additional, Ribeiro, Francinne Machado, additional, Rigante, Donato, additional, Rigopoulou, Eirini I., additional, Rose, Noel R., additional, Rosário, Cristina, additional, Rovenský, J., additional, Sakkas, Lazaros I., additional, Sarzi-Puttini, Piercarlo, additional, Seguro, Luciana Parente Costa, additional, Semino, Margherita, additional, Shoenfeld, Yehuda, additional, Silva, S., additional, Simonin, Laurent, additional, Smyk, Daniel S., additional, Sousa, Rita Catarina Medeiros, additional, Stagnaro, C., additional, Steere, Allen C., additional, Strle, Klemen, additional, Tektonidou, Maria G., additional, Tishler, Moshe, additional, Tomer, Yaron, additional, Toubi, Elias, additional, Tsokos, George C., additional, Vadasz, Zahava, additional, Valesini, Guido, additional, Vasconcelos, Carlos, additional, Vasconcelos, Júlia, additional, Vassilopoulos, Dimitrios, additional, Venkatesha, Shivaprasad H., additional, Vento, Sandro, additional, Viale, Christophe, additional, Villanueva, Ronald, additional, Vita, Pedro, additional, Wilson, Clyde, additional, Youinou, Pierre, additional, Záňová, E., additional, Zandman-Goddard, Gisele, additional, and Zen, M., additional

Published
2015
Full Text
View/download PDF

34. Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria

Author

Rozenbaum Michael, Lidar Merav, Rimar Doron, Slobodin Gleb, Sabag D Adi, Vadasz Zahava, Rosner Itzhak, Eiza Nasrin, and Toubi Elias

Subjects
medicine.medical_specialty, genetic structures, Immunology, Lupus nephritis, Urine, Semaphorins, Gastroenterology, Excretion, immune system diseases, Internal medicine, medicine, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, skin and connective tissue diseases, Proteinuria, Systemic lupus erythematosus, business.industry, Semaphorin-3A, medicine.disease, Lupus Nephritis, Rheumatology, Rheumatoid arthritis, medicine.symptom, business, Nephritis, Biomarkers
Abstract

Background: Immune semaphorins are important players in controlling both innate and adaptive immune responses. The regulatory role of semaphorin3A (sema3A) in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases is widely reported. Decreased levels of serum sema3A were shown to be associated with SLE disease activity. Objectives: To assess urine concentrations of sema3A in SLE patients and its correlation with renal involvement and disease activity. Methods: Urine levels of sema3A were analyzed in 38 SLE patients of whom 13 had renal involvement and were compared to 10 healthy controls and 8 RA patients (disease control group). Results: The secretion of urine sema3A was found to be significantly lower in SLE patients compared to healthy controls and RA patients (4.9±3.9 ng/ml, 8.5±2.7 ng/ml, 9.85±1.7 ng/ml, respectively, p = 0.0006). Urine sema3A was significantly lower in SLE patients with lupus nephritis than in patients without nephritis (4.0±3.4 ng/ml vs 6.5±3.8 ng/ml, p=0.03). Urine sema3A was inversely correlated with proteinuria and SLE disease activity. Conclusion: Urine sema3A is decreased in lupus patients and should be further evaluated as a possible biomarker for disease activity and renal involvement.

Published
2021

35. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Zuberbier, Torsten, primary, Abdul Latiff, Amir Hamzah, additional, Abuzakouk, Mohamed, additional, Aquilina, Susan, additional, Asero, Riccardo, additional, Baker, Diane, additional, Ballmer‐Weber, Barbara, additional, Bangert, Christine, additional, Ben‐Shoshan, Moshe, additional, Bernstein, Jonathan A., additional, Bindslev‐Jensen, Carsten, additional, Brockow, Knut, additional, Brzoza, Zenon, additional, Chong Neto, Herberto Jose, additional, Church, Martin K., additional, Criado, Paulo R., additional, Danilycheva, Inna V., additional, Dressler, Corinna, additional, Ensina, Luis Felipe, additional, Fonacier, Luz, additional, Gaskins, Matthew, additional, Gáspár, Krisztian, additional, Gelincik, Aslı, additional, Giménez‐Arnau, Ana, additional, Godse, Kiran, additional, Gonçalo, Margarida, additional, Grattan, Clive, additional, Grosber, Martine, additional, Hamelmann, Eckard, additional, Hébert, Jacques, additional, Hide, Michihiro, additional, Kaplan, Allen, additional, Kapp, Alexander, additional, Kessel, Aharon, additional, Kocatürk, Emek, additional, Kulthanan, Kanokvalai, additional, Larenas‐Linnemann, Désirée, additional, Lauerma, Antti, additional, Leslie, Tabi A., additional, Magerl, Markus, additional, Makris, Michael, additional, Meshkova, Raisa Y., additional, Metz, Martin, additional, Micallef, Daniel, additional, Mortz, Charlotte G., additional, Nast, Alexander, additional, Oude‐Elberink, Hanneke, additional, Pawankar, Ruby, additional, Pigatto, Paolo D., additional, Ratti Sisa, Hector, additional, Rojo Gutiérrez, María Isabel, additional, Saini, Sarbjit S., additional, Schmid‐Grendelmeier, Peter, additional, Sekerel, Bulent E., additional, Siebenhaar, Frank, additional, Siiskonen, Hanna, additional, Soria, Angele, additional, Staubach‐Renz, Petra, additional, Stingeni, Luca, additional, Sussman, Gordon, additional, Szegedi, Andrea, additional, Thomsen, Simon Francis, additional, Vadasz, Zahava, additional, Vestergaard, Christian, additional, Wedi, Bettina, additional, Zhao, Zuotao, additional, and Maurer, Marcus, additional

Published
2021
Full Text
View/download PDF

38. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Zuberbier, Torsten; Abdul Latiff, Amir Hamzah; Abuzakouk, Mohamed; Aquilina, Susan; Asero, Riccardo; Baker, Diane; Ballmer-Weber, Barbara; Bangert, Christine; Ben-Shoshan, Moshe; Bernstein, Jonathan A.; Bindslev-Jensen, Carsten; Brockow, Knut; Brzoza, Zenon; Chong Neto, Herberto Jose; Church, Martin K.; Criado, Paulo R.; Danilycheva, Inna V.; Dressler, Corinna; Ensina, Luis Felipe; Fonacier, Luz; Gaskins, Matthew; Gaspar, Krisztian; Gelincik, Asli; Gimenez-Arnau, Ana; Godse, Kiran; Goncalo, Margarida; Grattan, Clive; Grosber, Martine; Hamelmann, Eckard; Hebert, Jacques; Hide, Michihiro; Kaplan, Allen; Kapp, Alexander; Kessel, Aharon; Kulthanan, Kanokvalai; Larenas-Linnemann, Desiree; Lauerma, Antti; Leslie, Tabi A.; Magerl, Markus; Makris, Michael; Meshkova, Raisa Y.; Metz, Martin; Micallef, Daniel; Mortz, Charlotte G.; Nast, Alexander; Oude-Elberink, Hanneke; Pawankar, Ruby; Pigatto, Paolo D.; Ratti Sisa, Hector; Rojo Gutierrez, Maria Isabel; Saini, Sarbjit S.; Schmid-Grendelmeier, Peter; Sekerel, Bulent E.; Siebenhaar, Frank; Siiskonen, Hanna; Soria, Angele; Staubach-Renz, Petra; Stingeni, Luca; Sussman, Gordon; Szegedi, Andrea; Thomsen, Simon Francis; Vadasz, Zahava; Vestergaard, Christian; Wedi, Bettina; Zhao, Zuotao; Maurer, Marcus, School of Medicine, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Zuberbier, Torsten; Abdul Latiff, Amir Hamzah; Abuzakouk, Mohamed; Aquilina, Susan; Asero, Riccardo; Baker, Diane; Ballmer-Weber, Barbara; Bangert, Christine; Ben-Shoshan, Moshe; Bernstein, Jonathan A.; Bindslev-Jensen, Carsten; Brockow, Knut; Brzoza, Zenon; Chong Neto, Herberto Jose; Church, Martin K.; Criado, Paulo R.; Danilycheva, Inna V.; Dressler, Corinna; Ensina, Luis Felipe; Fonacier, Luz; Gaskins, Matthew; Gaspar, Krisztian; Gelincik, Asli; Gimenez-Arnau, Ana; Godse, Kiran; Goncalo, Margarida; Grattan, Clive; Grosber, Martine; Hamelmann, Eckard; Hebert, Jacques; Hide, Michihiro; Kaplan, Allen; Kapp, Alexander; Kessel, Aharon; Kulthanan, Kanokvalai; Larenas-Linnemann, Desiree; Lauerma, Antti; Leslie, Tabi A.; Magerl, Markus; Makris, Michael; Meshkova, Raisa Y.; Metz, Martin; Micallef, Daniel; Mortz, Charlotte G.; Nast, Alexander; Oude-Elberink, Hanneke; Pawankar, Ruby; Pigatto, Paolo D.; Ratti Sisa, Hector; Rojo Gutierrez, Maria Isabel; Saini, Sarbjit S.; Schmid-Grendelmeier, Peter; Sekerel, Bulent E.; Siebenhaar, Frank; Siiskonen, Hanna; Soria, Angele; Staubach-Renz, Petra; Stingeni, Luca; Sussman, Gordon; Szegedi, Andrea; Thomsen, Simon Francis; Vadasz, Zahava; Vestergaard, Christian; Wedi, Bettina; Zhao, Zuotao; Maurer, Marcus, and School of Medicine

Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA(2)LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria., Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs); European Union (EU); 6th Framework Programme; Global Allergy and Asthma European Network (GA2LEN); European Academy of Allergology and Clinical Immunology (EAACI); Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI); European Dermatology Forum (EDF)

Published
2021

41. The Emerging Role of IL-17 in the Immune-Pathogenesis of Chronic Spontaneous Urticaria

Author

Toubi,Elias and Vadasz,Zahava

Subjects
ImmunoTargets and Therapy
Abstract

Elias Toubi,1 Zahava Vadasz2 1The Outpatient Allergy Clinic, The Holy Family Hospital, Nazareth, Israel; 2The Proteomic Unit, The Division of Clinical Immunology, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, IsraelCorrespondence: Zahava Vadasz Email zahava.vadas@b-zion.org.ilAbstract: Chronic spontaneous urticaria (CSU) is considered to be an autoimmune disorder (type I and type II) in 50% of all cases. However, autoreactive T cells and their proximity with activated mast cells in the skin of CSU patients are believed to be the primary event in mast cell degranulation. The finding of anti-FcɛRIα on mast cells or IgE autoantibodies against thyroid antigens should be considered to be a consequence of the auto-reactive T cells’ recognition of the above-mentioned antigens. Our recent finding of increased Th17 and IL-17 expression in both CD4+ T cells and mast cells in the skin of severe CSU patients is supportive for the major role that T cells perform in the pathogenesis of CSU. Supporting this are numerous previous reports in which increased serum IL-17 was found to be in association with CSU disease severity. The beneficial effect of anti-IL-17A (secukinumab) in CSU patients in whom high dose anti-histamines, recurrent course of steroids and omalizumab fail to achieve a reasonable response should be investigated as a new therapeutic strategy in future studies with a large cohort of patients.Keywords: IL-17, interleukin-17, chronic spontaneous urticaria, CSU, T cells, mast cells

Published
2020

44. Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?

Author

Willner, Nadav, Goldberg, Yair, Schiff, Elad, and Vadasz, Zahava

Subjects
Inflammation, Adult, Aged, 80 and over, Antigens, Differentiation, T-Lymphocyte, Heart Failure, Male, Semaphorin 4D, Semaphorins, Middle Aged, NT‐proBNP, Severity of Illness Index, Peptide Fragments, Antigens, CD, Predictive Value of Tests, Original Research Articles, Acute Disease, Natriuretic Peptide, Brain, Disease Progression, Humans, Female, Original Research Article, Biomarkers, Aged
Abstract

Aims Semaphorin 4D (Sema4D) is expressed on platelets and T‐cells and known to be involved in inflammation. The aims of this study include comparing Sema4D and N terminal pro brain natriuretic peptide (NT‐proBNP) serum levels in heart failure (HF) patients to a control group, evaluating the correlation between Sema4D and NT‐proBNP levels, and assessing Sema4D serum levels in HF patients during acute exacerbation and remission. Methods and results Forty‐five patients diagnosed with HF (based on echocardiographic findings, positive NT‐proBNP levels, and normal C‐reactive protein) and 11 healthy controls (declaring no chronic diseases or medications) comprised the study population. Demographic, clinical, laboratory, and echocardiographic data were used to create the study database. NT‐proBNP and Sema4D serum samples were taken on admission and discharge. NT‐proBNP levels were significantly higher in the HF group than in controls (P

Published
2018

46. The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, primary, Salman, Andaç, additional, Cherrez‐Ojeda, Ivan, additional, Criado, Paulo Ricardo, additional, Peter, Jonny, additional, Comert‐Ozer, Elif, additional, Abuzakouk, Mohamed, additional, Agondi, Rosana Câmara, additional, Al‐Ahmad, Mona, additional, Altrichter, Sabine, additional, Arnaout, Rand, additional, Arruda, Luisa Karla, additional, Asero, Riccardo, additional, Bauer, Andrea, additional, Ben‐Shoshan, Moshe, additional, Bernstein, Jonathan A., additional, Bizjak, Mojca, additional, Boccon‐Gibod, Isabelle, additional, Bonnekoh, Hanna, additional, Bouillet, Laurence, additional, Brzoza, Zenon, additional, Busse, Paula, additional, Campos, Regis A, additional, Carne, Emily, additional, Conlon, Niall, additional, Criado, Roberta F., additional, de Souza Lima, Eduardo M., additional, Demir, Semra, additional, Dissemond, Joachim, additional, Doğan Günaydın, Sibel, additional, Dorofeeva, Irina, additional, Ensina, Luis Felipe, additional, Ertaş, Ragıp, additional, Ferrucci, Silvia Mariel, additional, Figueras‐Nart, Ignasi, additional, Fomina, Daria, additional, Franken, Sylvie M, additional, Fukunaga, Atsushi, additional, Giménez‐Arnau, Ana M., additional, Godse, Kiran, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Grattan, Clive, additional, Guillet, Carole, additional, Inomata, Naoko, additional, Jakob, Thilo, additional, Karakaya, Gul, additional, Kasperska‐Zając, Alicja, additional, Katelaris, Constance H, additional, Košnik, Mitja, additional, Krasowska, Dorota, additional, Kulthanan, Kanokvalai, additional, Kumaran, M. Sendhil, additional, Lang, Claudia, additional, Larco‐Sousa, José Ignacio, additional, Lazaridou, Elisavet, additional, Leslie, Tabi Anika, additional, Lippert, Undine, additional, llosa, Oscar Calderón, additional, Makris, Michael, additional, Marsland, Alexander, additional, Medina, Iris V., additional, Meshkova, Raisa, additional, Palitot, Esther Bastos, additional, Parisi, Claudio A.S., additional, Pickert, Julia, additional, Ramon, German D., additional, Rodríguez‐Gonzalez, Mónica, additional, Rosario, Nelson, additional, Rudenko, Michael, additional, Rutkowski, Krzysztof, additional, Sánchez, Jorge, additional, Schliemann, Sibylle, additional, Sekerel, Bulent Enis, additional, Serpa, Faradiba S., additional, Serra‐Baldrich, Esther, additional, Song, Zhiqiang, additional, Soria, Angèle, additional, Staevska, Maria, additional, Staubach, Petra, additional, Tagka, Anna, additional, Takahagi, Shunsuke, additional, Thomsen, Simon Francis, additional, Treudler, Regina, additional, Vadasz, Zahava, additional, Valle, Solange Oliveira Rodrigues, additional, Van Doorn, Martijn B.A., additional, Vestergaard, Christian, additional, Wagner, Nicola, additional, Wang, Dahu, additional, Wang, Liangchun, additional, Wedi, Bettina, additional, Xepapadaki, Paraskevi, additional, Yücel, Esra, additional, Zalewska‐Janowska, Anna, additional, Zhao, Zuotao, additional, Zuberbier, Torsten, additional, and Maurer, Marcus, additional

Published
2020
Full Text
View/download PDF

49. New Biological Treatment Options in CSU

Author

Vadasz, Zahava and Toubi, Elias

Subjects
Medical
Abstract

Chronic spontaneous urticaria (CSU) is a devastating disease and is associated with many co-morbidities and long-lasting suffering. Therefore, patients always look for a most efficient therapeutic approach to achieve a full remission. In many patients, CSU remain refractory to off-label doses of antihistamines and short courses of steroids, and therefore are treated with omalizumab. However, 15–20% of severe CSU patients will stay unresponsive to omalizumab and are defined as being of un-met needs. In this review we will shed light on the many new drugs which are assessed in ongoing clinical trials.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results